Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer.
Tsoli M, Wadham C, Pinese M, Failes T, Joshi S, Mould E, Yin JX, Gayevskiy V, Kumar A, Kaplan W, Ekert PG, Saletta F, Franshaw L, Liu J, Gifford A, Weber MA, Rodriguez M, Cohn RJ, Arndt G, Tyrrell V, Haber M, Trahair T, Marshall GM, McDonald K, Cowley MJ, Ziegler DS.
Tsoli M, et al. Among authors: ziegler ds.
Cancer Biol Ther. 2018;19(12):1078-1087. doi: 10.1080/15384047.2018.1491498. Epub 2018 Oct 9.
Cancer Biol Ther. 2018.
PMID: 30299205
Free PMC article.